Whats good for the goose is good for the gander is an old adage that should apply to pharmacy benefit managers, who are responsible for administering many prescription drug plans.
Using the justification of ensuring pharmacies are an honest broker in the delivery of these services, PBMs routinely and aggressively audit their books and retract money from the pharmacy whenever they can. However, turnabout is not fair play, as PBMs routinely deny health plan sponsors similar access to their business dealings. This needs to stop, and a good starting point is with the Federal Employees Health Benefits Program for employees, dependents and retirees.
Thats why Rep. Stephen Lynch (D-Mass.) recently introduced H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. The subject of a Congressional hearing this month, it could serve as a model for other health plans and expose the litany of secretive shell games that seemingly increase PBM profits at the expense of plan sponsors, patients and pharmacies.
For example, because PBMs manage the formularies a list of medications that determine what prescription drugs can be used for health plans, drug manufacturers will pay them rebates for promoting certain brand-name drugs over others. The PBMs retain large shares of these payments before passing on whatever might be left to plan sponsors. The more the preferred drug is dispensed, the greater the rebate revenue for the PBM. This can lead to profit-driven coverage decisions that favor pricier name-brand drugs over more inexpensive generic drugs. Little, if any, of this is disclosed to plan sponsors or patients.
In his capacity as chairman of the Oversight and Government Reform Subcommittee on Federal Workforce, Postal Service and the District of Columbia, Congressman Lynch previously held a hearing examining the largest FEHBP contract with the giant merged PBM, pharmacy chain and mail-order pharmacy CVS Caremark (Medco Health Solutions is a PBM and mail-order pharmacy with a smaller role). At the time, Lynch said, Its a scam of major proportions. When were trying to find billions of dollars to fund health care reform, this is an area that absolutely has to be cleaned up.
H.R. 4489 would empower the Office of Personnel Management with increased oversight over the PBMs for FEHBP, which has seen its cost soar 69 percent in the last eight years. It would:
Provide the OPM with access to reports on the rebates collected from drug manufacturers and require PBMs to pass through 99 percent of rebates and other compensation earned on behalf of plan members.
Halt PBMs practice of reimbursing mail-order pharmacies (which they own) at a higher rate than they would reimburse community pharmacies for the same prescription.
Stop PBM drug switching unless the change is approved by the provider and results in actual savings to the plan and patient.